DNDina Nair

Dina Nair

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dina Nair has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Soumya Swaminathan

    Indian Council of Medical Research, New Delhi, India

    3 shared publications
  • Banurekha Velayutham

    Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India

    2 shared publications
  • Basilea Watson

    National Institute for Research in Tuberculosis, Chennai, India

    2 shared publications
  • Jaya Prasad Tripathy

    International Union against Tuberculosis and Lung Disease, The Union South-East Asia Office, New Delhi, India

    2 shared publications
  • A. D. Harries

    The Union, Paris, France

    1 shared publication
  • Anthony D. Harries

    International Union Against Tuberculosis and Lung Disease, Paris, France

    1 shared publication

Latest Publications

  • Effect of moxifloxacin on QTc interval in adults with pulmonary tuberculosis

    by Dina Nair, Banurekha Velayutham, Makeshkumar Marimuthu, Poorana Ganga Devi Navaneethapandian, Ponnuraja Chinnaiyan, Mohammed Shaheed Jawahar, Soumya Swaminathan

    The National Medical Journal of India, India


  • Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India

    by D. Nair, B. Velayutham, T. Kannan, J. P. Tripathy, A. D. Harries, M. Natrajan, S. Swaminathan

    Setting: India has one of the highest global rates of multidrug-resistant tuberculosis (MDR-TB), which is associated with poor treatment outcomes. A better understanding of the risk factors for unfavourable outcomes is needed. Objectives: To describe 1) the demographic and clinical characteristics of MDR-TB patients registered in three states of India during 2009–2011, 2) treatment outcomes, and 3) factors associated with unfavourable outcomes. Design: A retrospective cohort study involving a record review of registered MDR-TB patients. Results: Of 788 patients, 68% were male, 70% were aged 15–44 years, 90% had failed previous anti-tuberculosis treatment or were retreatment smear-positive, 60% had a body mass index < 18.5 kg/m 2 and 72% had additional resistance to streptomycin and/or ethambutol. The median time from sputum collection to the start of MDR-TB treatment was 128 days (IQR 103–173). Unfavourable outcomes occurred in 40% of the patients, mostly from death or loss to follow-up. Factors significantly associated with unfavourable outcomes included male sex, age  45 years, being underweight and infection with the human immunodeficiency virus. Adverse drug reactions were reported in 24% of patients, with gastrointestinal disturbance, psychiatric morbidity and ototoxicity the most common. Conclusion: Long delays from sputum collection to treatment initiation using conventional methods, along with poor treatment outcomes, suggest the need to scale up rapid diagnostic tests and shorter regimens for MDR-TB.


  • Open Access

    Household Contact Screening and Yield of Tuberculosis Cases—A Clinic Based Study in Chennai, South India

    by Dina Nair, Nandita Rajshekhar, Joel Shyam Klinton, Basilea Watson, Banurekha Velayutham, Jaya Prasad Tripathy, Mohideen Shaheed Jawahar, Soumya Swaminathan

    Contact investigation is an active case finding strategy to increase detection of Tuberculosis (TB) and a key component of TB control programs. The household contacts are at a higher risk of exposure than members of the general population. The information on the value and yield of household contact screening and the approaches used in high incidence settings like India is limited. To evaluate the yield of active case finding in household contacts of newly diagnosed smear positive TB patients and the factors associated with increased yield. Retrospective record review of the household contacts of newly diagnosed sputum smear positive patients (index case) enrolled in a clinical trial at National Institute of Research in Tuberculosis, Chennai during the period 2007–2014. A sequential screening algorithm with chest x-ray followed by symptom screen was employed to identify presumptive TB patients. 643 household contacts of 280 index TB patients were identified out of which 544 (85%) consented for screening. 71/544 (13%) patients had an abnormal chest radiograph and out of them 70% were symptomatic. A total of 29/544 (5.3%) contacts were found to have TB among whom 23/29 (79%) were sputum smear positive. The number needed to screen (NNS) to identify a new TB case among all household contacts was 19 and among those with an abnormal CXR was 02. Age group > 44 years, male gender and siblings of the index case was associated with abnormal chest radiograph whereas age group between 15–44 was significantly associated with developing TB disease among household contacts. Active screening among household contacts is an effective way to improve TB case detection. The yield for new TB cases among contacts with abnormal x-ray was high in this study and the use of Chest X-rays in combination with symptom screen is recommended.


  • Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India

    by Dina Nair, Pooranaganga D. Navneethapandian, Jaya Prasad Tripathy, Anthony D. Harries, Joel S. Klinton, Basilea Watson, Gomathi N. Sivaramakrishnan, Devarajulu S. Reddy, Lakshmi Murali, Mohan Natrajan, et al.

    India is replacing culture and drug sensitivity testing (CDST) with rapid molecular tests for diagnosing MDR-TB. We assessed the impact of rapid tests on time to initiation of treatment and outcomes in patients with MDR-TB compared with CDST. A retrospective cohort study involving MDR-TB patients from six districts in Tamil Nadu state, who underwent CDST (2010–2011) and rapid tests (2012–2013). There were 135 patients in the CDST group and 389 in the rapid diagnostic test group. Median time from sputum receipt at the laboratory to initiation of MDR-TB treatment was 130 days (IQR 75–213) in the CDST group and 22 days (IQR 14–38) in the rapid diagnostic test group (p30 days (aRR 1.3, 95% CI 1.0–1.6). Rapid molecular diagnostic tests shortened the time to initiate treatment which was associated with reduced unfavourable outcomes in MDR-TB patients. This supports the policy to scale up these tests in India.